The document discusses dengue vaccine development and research. It mentions three types of dengue vaccine candidates that are currently in phase 1 clinical trials: 1) Live attenuated vaccines such as TDEN PIV by GSK and Walter Reed Army Institute. 2) Vaccines using other viruses like E. Coli and vaccinia to deliver dengue antigens. 3) V180 by Merck uses Drosophila to deliver dengue antigens. The document provides references for further information on dengue vaccines, epidemiology, candidates in development, efficacy and safety trials, and communication challenges.
19. REFERENCES
1. WHO Dengue vaccine research. Available from:
http://www.who.int/immunization/research/development/dengue_vaccines/
2. Dengue Vaccine Initiative. Available from: http://www.denguevaccines.org/
3. Park. Textbook of Preventive And Social Medicine. 23rd Edition. Bhanot Publication
4. Dengue vaccine: WHO position paper – July 2016 Available from: http://www.who.int/wer/en/
5. Centers for Disease Control and Prevention, Atlanta. Dengue. Available from:
http://www.cdc.gov/dengue/
6. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: A review of
candidates in preclinical development. Vaccine. 2011;29(42):7276-7284.
7. Schwartz L, Halloran M, Durbin A, Longini I. The dengue vaccine pipeline: Implications for the
future of dengue control. Vaccine. 2015;33(29):3293-3298.
8. Hadinegoro S, Arredondo-García J, Capeding M, Deseda C, Chotpitayasunondh T, Dietze R et al.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. New England
Journal of Medicine. 2015;373(13):1195-1206
9. Carvalho A, Van Roy R, Andrus J. International Dengue Vaccine Communication and Advocacy:
Challenges and Way Forward. Expert Review of Vaccines. 2016;15(4):539-545
19